Exclusive Summary

• The capsule formulation offers a differentiated competitive edge, providing better moisture resistance and easier patient swallowing compared to traditional tablets.
• A massive global base of over 1.28 billion hypertensive patients ensures stable, high-frequency, and long-term market demand for this first-line drug.
• Its impressive 24-hour half-life delivers superior clinical benefits, making it a guideline-recommended first-line therapy for cardiovascular risk reduction.
• Backed by China's highly mature API and formulation supply chain, it boasts significant cost advantages, ensuring lucrative profit margins for overseas distributors.